Abstract
The mononuclear complex, [Co(TAMEN)](ClO4)2(DMSO), containing the Mannich base N,N'-tetra-(4- antipyrylmethyl)-1,2-diaminoethane (TAMEN) as ligand, was synthesized and characterised by conductometric, electronic and infrared spectroscopic properties. The single-crystal X-ray structure show the presence of two well defined units, [Co(TAMEN)]2+ and (ClO4)-. The complex cation contains cobalt(II) in the pseudo octahedral environment created by the N2O4 donor set of TAMEN. The cobalt(II) complex have been screened for its cytotoxic activity against three cultured human cell lines established from hepatoma (Hep G2), breast (MCF-7) and lung (A549) cancers as well as on nontumor bovine kidney (MDBK) cells. The cytotoxic activity of the ligand TAMEN was assessed on one tumor (Hep G2) and one non-tumor (MDBK) cell lines. The cobalt(II) compound was found to decrease in a time- and concentration- dependent manner the viability of tumor (A549, MCF-7, Hep G2) cell lines, while the ligand TAMEN expressed proliferative activity on hepatoma (HepG2) and bovine kidney (MDBK) cells, especially after prolonged incubation.
Keywords: Cobalt (II), mannich base, cell viability/proliferation
Medicinal Chemistry
Title:Crystal Structure and Cytotoxic Activity of Co(II) Complex Containing N,N’-Tetra-(4-Antipyrylmethyl)-1,2-Diaminoethane (TAMEN) as Ligand
Volume: 6 Issue: 5
Author(s): Elena Maria Mosoarca, Ingo Pantenburg, Ramona Tudose, Gerd Meyer, Radostina Alexandrova, Reni Kalfin, Wolfgang Linert and Otilia Costisor
Affiliation:
Keywords: Cobalt (II), mannich base, cell viability/proliferation
Abstract: The mononuclear complex, [Co(TAMEN)](ClO4)2(DMSO), containing the Mannich base N,N'-tetra-(4- antipyrylmethyl)-1,2-diaminoethane (TAMEN) as ligand, was synthesized and characterised by conductometric, electronic and infrared spectroscopic properties. The single-crystal X-ray structure show the presence of two well defined units, [Co(TAMEN)]2+ and (ClO4)-. The complex cation contains cobalt(II) in the pseudo octahedral environment created by the N2O4 donor set of TAMEN. The cobalt(II) complex have been screened for its cytotoxic activity against three cultured human cell lines established from hepatoma (Hep G2), breast (MCF-7) and lung (A549) cancers as well as on nontumor bovine kidney (MDBK) cells. The cytotoxic activity of the ligand TAMEN was assessed on one tumor (Hep G2) and one non-tumor (MDBK) cell lines. The cobalt(II) compound was found to decrease in a time- and concentration- dependent manner the viability of tumor (A549, MCF-7, Hep G2) cell lines, while the ligand TAMEN expressed proliferative activity on hepatoma (HepG2) and bovine kidney (MDBK) cells, especially after prolonged incubation.
Export Options
About this article
Cite this article as:
Maria Mosoarca Elena, Pantenburg Ingo, Tudose Ramona, Meyer Gerd, Alexandrova Radostina, Kalfin Reni, Linert Wolfgang and Costisor Otilia, Crystal Structure and Cytotoxic Activity of Co(II) Complex Containing N,N’-Tetra-(4-Antipyrylmethyl)-1,2-Diaminoethane (TAMEN) as Ligand, Medicinal Chemistry 2010; 6 (5) . https://dx.doi.org/10.2174/157340610793358882
DOI https://dx.doi.org/10.2174/157340610793358882 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Safety, Efficacy and Therapeutic Potential of Histone Deacetylase Inhibitors with Special Reference to Panobinostat in Gastrointestinal Tumors: A Review of Preclinical and Clinical Studies
Current Cancer Drug Targets Predictive Efficacy Biomarkers of Programmed Cell Death 1/Programmed Cell Death 1 Ligand Blockade Therapy
Recent Patents on Anti-Cancer Drug Discovery Oncogene Expression Modulation in Cancer Cell Lines by DNA G-Quadruplex-Interactive Small Molecules
Current Medicinal Chemistry Editorial from Editor-in-Chief
Current Medical Imaging Protein Kinase C and Oxidative Stress in an Animal Model of Mania
Current Neurovascular Research Identification of AHSA1 as a Potential Therapeutic Target for Breast Cancer: Bioinformatics Analysis and <i>in vitro</i> Studies
Current Cancer Drug Targets Sphere Formation Assay is not an Effective Method for Cancer Stem Cell Derivation and Characterization from the Caco-2 Colorectal Cell Line
Current Stem Cell Research & Therapy TGF-β Receptor Signaling Pathways in Angiogenesis; Emerging Targets for Anti-Angiogenesis Therapy
Current Pharmaceutical Biotechnology To Investigate Growth Factor Receptor Targets and Generate Cancer Targeting Inhibitors
Current Topics in Medicinal Chemistry Drug Conjugated Nanomedicine as Prodrug Carrier
Nanoscience & Nanotechnology-Asia Clinical Next Generation Sequencing for Precision Medicine in Cancer
Current Genomics Targeting Breast Cancer Cells with G4 PAMAM Dendrimers and Valproic Acid Derivative Complexes
Anti-Cancer Agents in Medicinal Chemistry Positron Emission Tomography: Applications In Drug Discovery and Drug Development
Current Topics in Medicinal Chemistry The PI3 Kinase Signaling Pathway in Prostate Cancer
Current Cancer Drug Targets Poly(ADP-Ribose) Polymerase-1 Inhibitors Drug Discovery, Design, and Development as Anticancer Agents from Past to Present: A Mini-Review
Mini-Reviews in Medicinal Chemistry Induction of Apoptosis by Curcumin and Its Implications for Cancer Therapy
Current Cancer Drug Targets Breast Infrared Thermography Segmentation Based on Adaptive Tuning of a Fully Convolutional Network
Current Medical Imaging Metabolic Basis of Polycystic Ovarian Syndrome; Indications for Biochemical Screening
Endocrine, Metabolic & Immune Disorders - Drug Targets Fibroblast Growth Factors, Fibroblast Growth Factor Receptors, Diseases, and Drugs
Recent Patents on Cardiovascular Drug Discovery Amniotic Fluid Stem Cells: a Promising Therapeutic Resource for Cell-Based Regenerative Therapy
Current Pharmaceutical Design